The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations
K M Higgins, Olga P. Nyssen, Joshua Southern, Ivan Laponogov, Ana Miralles-Marco, Manuel Cabeza-Segura, Elena Jiménez-Martí, Josefa Castillo, Mārcis Leja, Inese Poļaka, Fátima Carneiro, Céu Figueiredo, Rui M. Ferreira, Rita Barros, Letícia Moreira, Míriam Cuatrecasas, Glòria Fernández‐Esparrach, Tamara Matysiak-Budnik, J.P. Martin, Laimas Virginijus Jonaitis, Juozas Kupčinskas, Paulius Jonaitis, Mário Dinis‐Ribeiro, Miguel Coimbra, Ana Carina Pereira, Filipa Fontes, Manon C.W. Spaander, Judith Honing, Stefano Sedola, Junior Andrea Pescino, Zorana Maravic, Ana Martins, Dennis A. Veselkov, Javier P. Gisbert, Tania Fleitas, Kirill Veselkov
Abstract
Helicobacter pylori (H. pylori) is the most common carcinogenic pathogen globally and the leading cause of gastric cancer. Here, we develop a reinforcement learning-based AI Clinician system to personalise treatment selection and evaluate its ability to improve eradication success compared to clinician-prescribed therapies. The model is trained and internally validated on 38,049 patients from the retrospective European Registry on Helicobacter pylori Management (Hp-EuReg), using independent state deep Q-learning (isDQN) to recommend optimal therapies based on patient characteristics such as age, sex, antibiotic allergies, country, and pre-treatment indication. In internal validation using real-world Hp-EuReg data, AI-recommended therapies achieve a 94.1% success rate (95% CI: 93.2-95.0%) versus 88.1% (95% CI: 87.7-88.4%) for clinician-prescribed therapies not aligned with AI suggestions-an improvement of 6.0%. Results are replicated in an external validation cohort (n = 7186), confirming generalisability. The AI system identifies optimal treatment strategies in key subgroups: 65% (n = 24,923) are recommended bismuth-based therapies, and 15% (n = 5898) non-bismuth quadruple therapies. Random forest modelling identifies region and concurrent medications as patient-specific drivers of AI recommendations. With nearly half the global population likely to contract H. pylori, this approach lays the foundation for future prospective clinical validation and shows the potential of AI to support clinical decision-making, enhance outcomes, and reduce gastric cancer burden.